Jan Adams, MD. Grunethal, and its US subsidiary Averitas Pharma, announced that the FDA has approved capsaicin 8% patch (Qutenza) for the treatment of neuropathic pain associated with diabetic peripheral neuropathy (DPN) of the feet in adults. 1 It marks the second approval for Qutenza, which received the green light in 2009 for the management of neuropathic pain associated with postherpetic ...Jan 12, 2022 · #1 I am a facility coder for a hospital system that is primarily Medicare and Medicaid patients. I